R

Regenicin Inc
OTC:RGIN

Watchlist Manager
Regenicin Inc
OTC:RGIN
Watchlist
Price: 0.0003 USD Market Closed
Market Cap: $153

Net Margin

0%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Net
Margin
US
Regenicin Inc
OTC:RGIN
153 USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
NL
argenx SE
XBRU:ARGX
43.3B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
44.6B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
274.1B CNY
Loading...
DE
BioNTech SE
NASDAQ:BNTX
27.5B USD
Loading...
DK
Genmab A/S
CSE:GMAB
127.3B DKK
Loading...
US
United Therapeutics Corp
NASDAQ:UTHR
20B USD
Loading...
US
Incyte Corp
NASDAQ:INCY
19.6B USD
Loading...
US
Revolution Medicines Inc
NASDAQ:RVMD
18.7B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Regenicin Inc
Glance View

Market Cap
153 USD
Industry
N/A

Regenicin, Inc. is a biotechnology company, which specializes in the development of regenerative cell therapies to restore the health of damaged tissues and organs. The company is headquartered in Little Falls, New Jersey. The company went IPO on 2008-05-12. The firm is focused on developing and commercializing a lifesaving technology by the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is a graftable cultured epithelium skin substitute containing both epidermal and dermal components. The firm is focused on developing its product, TempaDerm. TempaDerm cells develop banks of cryo-preserved (frozen) cells and cultured skin substitute to provide a continuous supply of non-allogenic skin substitutes to treat smaller wound areas on patients, such as ulcers. Its application are used for treatment of chronic skin wounds.

RGIN Intrinsic Value
Not Available
R
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Back to Top